<i>In vitro</i> antimicrobial susceptibility of <i>Mycoplasma pneumoniae</i> isolates across different regions of China in 2023
During the 2023 epidemic, isolates of <i>M. pneumoniae</i> were highly resistant to macrolides but remained susceptible to tetracycline and quinolones. For the treatment of macrolide-resistant <i>M. pneumoniae</i>, tetracycline, moxifloxacin and doxycycline would be the recommended antibiotics based on our findings.
Authors
- X.Y. Liu
- Xue Ren
- Yanling Feng
- Jing Yuan (ORCID: https://orcid.org/0000-0002-6939-9676)
- Yujie Chen (ORCID: https://orcid.org/0000-0003-2513-7559)
- Chao Yan (ORCID: https://orcid.org/0000-0001-5624-8636)
- Hanqing Zhao (ORCID: https://orcid.org/0000-0003-4595-277X)
- Jinghua Cui (ORCID: https://orcid.org/0000-0001-8427-7784)
- Xinyu Jia
- Bing Du (ORCID: https://orcid.org/0000-0001-5570-648X)
- Guanhua Xue (ORCID: https://orcid.org/0000-0003-0272-3109)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Capital Institute of Pediatrics (CN)
- Beijing Children’s Hospital (CN)
Publication Details
- Journal
- JAC-Antimicrobial Resistance
- Published
- 2025-06-30
- DOI
- https://doi.org/10.1093/jacamr/dlaf124
- Citations
- 2
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 2.71
Funders
- Guangzhou Medical University
- Harbin Medical University
- National Natural Science Foundation of China
- Hunan Normal University
- Zhengzhou University
- Natural Science Foundation of Beijing Municipality
- China Medical University
- Soochow University
- Shengjing Hospital